Molecular Partners AG (MOLN) — Capital Reinvestment Ratio
Latest as of March 2022:
0.00x
Molecular Partners AG (MOLN) has a Capital Reinvestment Ratio of 0.00x as of March 2022, meaning it reinvests 0% of its operating cash flow (CHF163.56 Million) in capital expenditures (CHF380.00K). See Molecular Partners AG (MOLN) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
CHF163.56 Million
CHF
Capital Expenditures
CHF380.00K
CHF
Data as of
Mar 2022
Most recent filing
Molecular Partners AG Capital Reinvestment Ratio (2015–2022)
This chart tracks Molecular Partners AG's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Molecular Partners AG (2015–2022)
Year-by-year Capital Reinvestment Ratio for Molecular Partners AG from 2015 to 2022. For live market cap and broader valuation context, see market cap of Molecular Partners AG.
| Year | Reinvestment Ratio | Operating CF (CHF) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.01x | CHF118.57 Million | CHF1.42 Million | ▼ -77.2% |
| 2015 | 0.05x | CHF26.50 Million | CHF1.39 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow